Royce & Associates LP Buys Shares of 246,524 Indivior PLC $INDV

Royce & Associates LP purchased a new position in Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 246,524 shares of the company’s stock, valued at approximately $5,944,000. Royce & Associates LP owned about 0.18% of Indivior at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after buying an additional 1,299,425 shares during the last quarter. Jane Street Group LLC raised its stake in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in Indivior by 17.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after acquiring an additional 3,769 shares in the last quarter. Amalgamated Bank purchased a new stake in shares of Indivior during the second quarter worth about $61,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Indivior during the second quarter valued at about $768,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Insider Transactions at Indivior

In related news, Director David E. Wheadon purchased 1,771 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, with a total value of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares of the company’s stock, valued at $509,439.05. The trade was a 14.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark Stejbach acquired 775 shares of the stock in a transaction on Monday, January 5th. The stock was bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 16,847 shares in the company, valued at approximately $596,215.33. This represents a 4.82% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 4,871 shares of company stock valued at $172,385.

Indivior Price Performance

NASDAQ:INDV opened at $32.16 on Thursday. The company’s fifty day moving average price is $34.27 and its 200-day moving average price is $30.22. Indivior PLC has a 1-year low of $8.64 and a 1-year high of $38.00. The firm has a market capitalization of $4.02 billion, a P/E ratio of 19.61 and a beta of 0.83.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. The company had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. Equities analysts anticipate that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on INDV shares. Northland Securities set a $50.00 target price on shares of Indivior in a research note on Tuesday, January 20th. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday. Morgan Stanley reissued an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Finally, HC Wainwright raised their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Indivior currently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.